Literature DB >> 26876171

Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.

Giovanni Galletti1, Cristina Scielzo1, Federica Barbaglio2, Tania Véliz Rodriguez2, Michela Riba3, Dejan Lazarevic3, Davide Cittaro3, Giorgia Simonetti4, Pamela Ranghetti2, Lydia Scarfò5, Maurilio Ponzoni6, Martina Rocchi6, Angelo Corti7, Achille Anselmo8, Nico van Rooijen9, Christian Klein10, Carola H Ries11, Paolo Ghia12, Michele De Palma13, Federico Caligaris-Cappio14, Maria Teresa Sabrina Bertilaccio15.   

Abstract

The role of monocytes/macrophages in the development and progression of chronic lymphocytic leukemia (CLL) is poorly understood. Transcriptomic analyses show that monocytes/macrophages and leukemic cells cross talk during CLL progression. Macrophage depletion impairs CLL engraftment, drastically reduces leukemic growth, and favorably impacts mouse survival. Targeting of macrophages by either CSF1R signaling blockade or clodrolip-mediated cell killing has marked inhibitory effects on established leukemia also. Macrophage killing induces leukemic cell death mainly via the TNF pathway and reprograms the tumor microenvironment toward an antitumoral phenotype. CSF1R inhibition reduces leukemic cell load, especially in the bone marrow, and increases circulating CD20(+) leukemic cells. Accordingly, co-targeting TAMs and CD20-expressing leukemic cells provides a survival benefit in the mice. These results establish the important role of macrophages in CLL and suggest therapeutic strategies based on interfering with leukemia-macrophage interactions.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26876171     DOI: 10.1016/j.celrep.2016.01.042

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  36 in total

1.  TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.

Authors:  Adrian Wiestner; Sarah E M Herman; Eman L Dadashian; Erin M McAuley; Delong Liu; Arthur L Shaffer; Ryan M Young; Jessica R Iyer; Michael J Kruhlak; Louis M Staudt
Journal:  Cancer Res       Date:  2018-11-29       Impact factor: 12.701

2.  Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.

Authors:  Priyanka Banerjee; Ronghua Zhang; Cristina Ivan; Giovanni Galletti; Karen Clise-Dwyer; Federica Barbaglio; Lydia Scarfò; Miguel Aracil; Christian Klein; William Wierda; William Plunkett; Federico Caligaris-Cappio; Varsha Gandhi; Michael J Keating; Maria Teresa S Bertilaccio
Journal:  Cancer Immunol Res       Date:  2019-09-17       Impact factor: 11.151

3.  Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Authors:  Stephen E Kurtz; Christopher A Eide; Andy Kaempf; Vishesh Khanna; Samantha L Savage; Angela Rofelty; Isabel English; Hibery Ho; Ravi Pandya; William J Bolosky; Hoifung Poon; Michael W Deininger; Robert Collins; Ronan T Swords; Justin Watts; Daniel A Pollyea; Bruno C Medeiros; Elie Traer; Cristina E Tognon; Motomi Mori; Brian J Druker; Jeffrey W Tyner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-07       Impact factor: 11.205

4.  The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.

Authors:  J Wakim; E Arman; S Becker-Herman; M P Kramer; E Bakos; I Shachar; A Elson
Journal:  Oncogene       Date:  2017-02-06       Impact factor: 9.867

Review 5.  B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia.

Authors:  G Galletti; F Caligaris-Cappio; M T S Bertilaccio
Journal:  Leukemia       Date:  2016-09-28       Impact factor: 11.528

Review 6.  Targeting B cell receptor signalling in cancer: preclinical and clinical advances.

Authors:  Jan A Burger; Adrian Wiestner
Journal:  Nat Rev Cancer       Date:  2018-01-19       Impact factor: 60.716

7.  Bone marrow dendritic cells support the survival of chronic lymphocytic leukemia cells in a CD84 dependent manner.

Authors:  Avital F Barak; Hadas Lewinsky; Michal Perpinial; Victoria Huber; Lihi Radomir; Mattias P Kramer; Lital Sever; Yochai Wolf; Mika Shapiro; Yair Herishanu; Steffen Jung; Shirly Becker-Herman; Idit Shachar
Journal:  Oncogene       Date:  2019-11-26       Impact factor: 9.867

8.  CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.

Authors:  David K Edwards; Kevin Watanabe-Smith; Angela Rofelty; Alisa Damnernsawad; Ted Laderas; Adam Lamble; Evan F Lind; Andy Kaempf; Motomi Mori; Mara Rosenberg; Amanda d'Almeida; Nicola Long; Anupriya Agarwal; David Tyler Sweeney; Marc Loriaux; Shannon K McWeeney; Jeffrey W Tyner
Journal:  Blood       Date:  2018-11-13       Impact factor: 22.113

Review 9.  The Bone Marrow Niche in B-Cell Acute Lymphoblastic Leukemia: The Role of Microenvironment from Pre-Leukemia to Overt Leukemia.

Authors:  Erica Dander; Chiara Palmi; Giovanna D'Amico; Giovanni Cazzaniga
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

10.  CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.

Authors:  Matteo Grioni; Arianna Brevi; Elena Cattaneo; Alessandra Rovida; Jessica Bordini; Maria Teresa Sabrina Bertilaccio; Maurilio Ponzoni; Giulia Casorati; Paolo Dellabona; Paolo Ghia; Matteo Bellone; Arianna Calcinotto
Journal:  Blood Adv       Date:  2021-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.